Aceragen | Kortsiktig Gjeld

Current Liabilities Endring Dato
Abbott USD 14.35B 180M 2023-06
Alnylam Pharmaceuticals USD 967.79M 18M 2023-12
Alterity Therapeutics Limited AUD 4.38M 849.82K 2023-06
Amgen USD 18.39B 1.44B 2023-12
Biogen USD 3.43B 1.59B 2023-12
BioMarin Pharmaceutical USD 1.18B 13.8M 2023-12
Clal Biotechnology ILS 2.91M 173K 2022-12
Compugen USD 10.38M 425K 2023-09
CSL USD 4.61B 278.2M 2023-06
Dynavax Technologies USD 62.2M 7.93M 2023-12
Eli Lilly USD 22B 3.08B 2023-09
Gilead Sciences USD 11.28B 665M 2023-12
GlaxoSmithKline GBP 22.39B 282M 2023-09
Grifols EUR 2.03B 148.07M 2023-09
Merck USD 23.09B 300M 2023-09
Nektar Therapeutics USD 52.11M 1.42M 2023-09
Pfizer USD 31.14B 3.51B 2023-09
Roche Holding CHF 26.21B 1.03B 2023-06
Sarepta Therapeutics USD 450.74M 47.91M 2023-09
Ultragenyx Pharmaceutical USD 253.98M 9.6M 2023-09



Aceragen Kortsiktig Gjeld - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2024.